FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,163,616 | -55.5% | 3,379,064 | 0.0% | 2.64% | -47.2% |
Q2 2023 | $16,084,345 | -16.5% | 3,379,064 | 0.0% | 4.99% | -20.3% |
Q1 2023 | $19,260,665 | +56391.2% | 3,379,064 | 0.0% | 6.26% | -36.8% |
Q4 2022 | $34,095 | -100.0% | 3,379,064 | 0.0% | 9.92% | -55.5% |
Q3 2022 | $75,725,000 | -9.6% | 3,379,064 | 0.0% | 22.28% | +4.2% |
Q2 2022 | $83,733,000 | -36.1% | 3,379,064 | 0.0% | 21.39% | -13.6% |
Q1 2022 | $131,006,000 | -33.7% | 3,379,064 | 0.0% | 24.77% | +10.0% |
Q4 2021 | $197,709,000 | -1.3% | 3,379,064 | 0.0% | 22.51% | +28.1% |
Q3 2021 | $200,277,000 | – | 3,379,064 | – | 17.57% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |